Abstract
Thoracic aortic aneurysm (TAA) is a silent disease with indolent progression, but it is potentially lethal once its complication with acute aortic syndrome occurred. Hypertension, smoking and atherosclerosis had all along been recognized as the major risk factors for the etiology of TAA. However, with the advancement in genomic technology, we have gained a better understanding on the contribution of the hereditary components in the genetically triggered thoracic aortic aneurysm and dissection (GTAAD). From the literature, around 20% of patients with thoracic aortic aneurysm and dissection (TAAD) have a positive family history. Therefore, if these atrisk patients can be identified earlier by screening, risk factors control and timely intervention can be made to alter the unfavorable outcome. This article aims to review the current guideline, modes of screening and potential future role of multimodality risk assessment for TAA by integration with radiomics and radiogenomics as well as how screening can potentially alleviate the devastating complications to improve the clinical outcomes.
Recommended Citation
Ray TW Lum, Jacky YK Ho, Simon CY Chow, Takuya Fujikawa, Randolph HL Wong, Screening for thoracic aortic aneurysm Journal of the Hong Kong College of Cardiology 2024;31(4) https://doi.org/10.55503/2790-6744.1538
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.